Australia’s My Health Record system sees rise in data breaches

Healthcare IT News | January 14, 2019

The agency’s Annual Report 2017–18 identified that “42 data breaches (in 28 notifications) were reported to the Office of the Australian Information Commissioner (OAIC)… concerning potential data security or integrity breaches”, but with “no purposeful or malicious attacks compromising the integrity or security of the My Health Record system”. Of the 42 instances, one breach resulted from unauthorised access to a My Health Record as a result of an incorrect parental authorised representative being assigned to a child. Two breaches resulted from suspected fraud against the Medicare program, where the incorrect records appeared in the My Health Record of the affected individual and were viewed without authority by the individual undertaking the suspected fraudulent activity.

Spotlight

Do you know what’s really killing you? It’s not new or sensational, but plain old heart disease. Heart conditions that include diseased vessels, structural problems, and blood clots.


Other News
HEALTH TECHNOLOGY

Alkem Laboratories Ltd. to Launch State of the Art Technology for Diabetic Foot Ulcer Management

Alkem Laboratories Ltd. | January 13, 2022

Alkem Laboratories Ltd. (Alkem) hereby announces to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval. This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India. India currently has approximately 77 mn diabetes patients, the second highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes. Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead to limb amputation within 6–18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes. Alkem has collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient's quality of life and the associated economic burden on the healthcare system. "In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers." Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd Adding further, Mr. Sandeep asserted, "Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives." About Alkem Laboratories Ltd Established in 1973 and headquartered in Mumbai, Alkemis a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company also has presence in more than 40 international markets, with the United States being its key focus market.

Read More

HEALTHTECH SECURITY

Health Alliance Improves Outcomes and Reduces Costs Using CareSignal’s Deviceless Remote Patient Monitoring

CareSignal, Health Alliance | June 27, 2022

Health AllianceTM, the health plan of Illinois-based Carle Health, is leading the way for rising-risk populations by launching a remote patient monitoring program powered by CareSignal. This program is part of Hally® health, the member-facing telehealth app Health Alliance uses to give its members access to tools and resources for their well-being. The partnership between Health Alliance and CareSignal aims to reduce readmissions, reduce spending, and improve members’ experience while increasing health literacy and empowering members to better self-manage their chronic conditions. The partnership is serving shared Medicare and Commercial populations and is expanding to Carle Health’s Accountable Care Organization. CareSignal’s scalable remote patient monitoring technology sends evidence-based questions directly via phone call or text message to the member. Questions focus on the member’s health status and encourage adherence to their health management plan through reporting of symptoms and daily habits while monitoring changes in risk status. Indications of worsening symptoms can trigger real-time alerts to allow for intervention, including proactive health coaching and escalation of care. Health Alliance is currently prioritizing Chronic Obstructive Respiratory Disease congestive heart failure, hypertension, asthma, and post-discharge care, and is hoping to add additional populations. Health Alliance is also bolstering its care coordination team with CareSignal’s virtual care navigators enabling them to manage a larger member population without needing additional staff. VCNs are the first to intervene with members before escalating to the Health Alliance care coordination team and/or primary care physician. By handling routine review, education and scheduling tasks when needed, the VCNs enable the Health Alliance care coordination team to work at the top of their license. The program provides increased support for members without increased touch points from providers. “Our team selected CareSignal as the best fit for our Health Alliance remote patient monitoring strategy due to its clinically validated pathways, ability to scale, and ease of use for our members. We believe by adding remote patient monitoring to our population health services, we will improve quality of care and health outcomes, expand access to care management, reduce disparities in health outcomes, enhance the member experience, and reduce hospitalizations, ED visits, and readmission rates.” Margie Zeglen, MBA, FACHE, Vice President of Population Health at Health Alliance and Carle Health “The expansion of this relationship is a result of the clinical and strategic vision that Carle and Health Alliance teammates bring to our partnership,” said Blake Marggraff, CEO of CareSignal, a Lightbeam Company. “Given the ongoing, nationwide staffing challenges that healthcare organizations face, the CareSignal team is particularly proud to be able to support Health Alliance with both the technology and clinical resources required for success. I look forward to serving even more individuals’ clinical needs while simultaneously serving a terrific client-partner.” About Health Alliance Based in Champaign, IL, Health Alliance operates in Illinois, Iowa, Indiana, Ohio, and Washington with additional licenses in Nebraska and Missouri. Health Alliance is part of Carle Health, an integrated system of healthcare services, which includes a five-hospital system as multi-specialty physician groups, as well as Carle Illinois College of Medicine and the Stephens Family Clinical Research Institute. In Illinois, Health Alliance offers employer group plans, individual plans, Medicare plans, State of Illinois Employee plans, and State of Illinois Retiree plans through Total Retiree Advantage Illinois. In Iowa, Health Alliance offers employer group plans and Medicare plans. In Washington, we offer Medicare plans and public individual plans. And in Indiana and Ohio, Health Alliance offers Medicare plans. About CareSignal – a Lightbeam Health Solutions Company CareSignal offers Deviceless Remote Patient Monitoring® which is specifically designed for value-based care by leveraging real-time, self-reported patient data and artificial intelligence to produce long-term patient engagement while identifying clinically actionable moments for proactive care delivery. Together, Lightbeam and CareSignal align best-in-class population health capabilities with proven remote engagement and monitoring solutions serving more than 42 million patient lives across the United States. Lightbeam’s vision is to shine a light on health data using analytics, and to provide the insight and capabilities healthcare clients need to ensure patients receive the right care at the right time. Learn more about solutions specific to your organization and population by visiting our website or trying a self-guided demo.

Read More

FUTURE OF HEALTHCARE

Modivcare Announces Acquisition of Guardian Medical Monitoring

Modivcare Inc. | May 19, 2022

Modivcare Inc. a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes, announced the Company’s Remote Patient Monitoring Segment has acquired Guardian Medical Monitoring, LLC from its parent company, Guardian Alarm. Guardian Medical Monitoring is a leading provider of remote patient monitoring solutions to Managed Care Organizations and state Medicaid payors including Personal Emergency Response Systems and medication management. GMM’s RPM platform currently monitors approximately 50,000 aging and chronically ill patients on behalf of their respective payors. “Remote patient monitoring is essential to Modivcare’s mission to connect patients to care through our integrated supportive care platform. Our comprehensive remote patient monitoring offering allows patients to safely age in their homes with technology-enabled connectivity to care which increases patient engagement and reduces costs. We are excited to accelerate the growth of Modivcare’s RPM Segment with the acquisition of GMM, and we are excited to welcome the GMM team to Modivcare.” Daniel E. Greenleaf, Modivcare’s President and Chief Executive Officer Jason Anderson, President, Modivcare Home added, “Guardian Medical Monitoring is a complementary acquisition for Modivcare’s RPM Segment, strengthening our customer relationships and expanding our service footprint across key states. Additionally, this acquisition provides an opportunity to expand our E3 engagement platform across a larger base of members and payors. Modivcare’s E3 platform helps our partners reduce gaps in care and address social determinants of health by engaging, educating, and empowering members using our proprietary platform.” About Modivcare Modivcare Inc. is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation, personal care and remote patient monitoring.

Read More

HEALTH TECHNOLOGY

Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications

Microbot Medical | December 28, 2021

Microbot Medical Inc.announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures. “We have already ensured that the LIBERTY Robotic System has a strong and sustainable competitive advantage, and the collaboration with Stryker will allow us to further expand in the neurovascular space. I believe the similarities in our innovation culture, as well as our complementary core capabilities, will allow us to establish a truly differentiated solution that will benefit all stakeholders and accelerate our goal of changing the way robotic surgery is viewed and adopted.” Harel Gadot, Chairman, CEO and President of Microbot Medical The company will continue to develop the LIBERTY Robotic System independently for use in peripheral and coronary procedures. The animal feasibility studies to date support the company’s assertion that it will potentially allow physicians to safely and efficiently conduct remote catheter-based vascular procedures, and reduce the risk for radiation exposure, physical strain on the user and Hospital Acquired Infections (HAIs), without the need for cumbersome and expensive capital equipment. About Microbot Medical Microbot Medical Inc.is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP). Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies.

Read More

Spotlight

Do you know what’s really killing you? It’s not new or sensational, but plain old heart disease. Heart conditions that include diseased vessels, structural problems, and blood clots.

Resources